Fidelity Digital Health ETF (BATS:FDHT), Quote.Headers.trade-ideas

Healthcare

Industrials

Consumer Defensive

Financial Services

Other

Technology

Consumer Cyclical

Normally investing at least 80 percent of assets in securities included in the Fidelity Digital Health Index and in depositary receipts representing securities included in the index. The Fidelity Digital Health Index is designed to reflect the performance of a global universe of companies across the market capitalization spectrum providing healthcare records management, connected healthcare devices, surgical robotics, telemedicine, and other technology-enabled healthcare products and services.

Intuitive Surgical Inc

Dexcom, Inc

Resmed Inc.

Koninklijke Philips Nv

Insulet Corp

Cochlear Ltd

Sonova Holding Ag

Fisher & Paykel Healthcare Corp Ltd

Fidelity Digital Health ETF

FIDELITY UCITS ICAV ETF

<p>Despite California's cannabis market facing historic lows, there's been a notable surge in demand for cannabis businesses. The paradox arises from the complex dynamics within the industry, where economic downturns and heightened competition have pushed prices down, yet consumer interest and business opportunities remain robust.</p>
<p>California&#8217;s cannabis market, once projected to soar post-legalization, has seen a decline in wholesale prices and revenues due to overproduction, regulatory hurdles, and competition from the illicit market. Many businesses are struggling with shrinking profit margins, excessive taxation, and operational costs. However, these challenges have also created opportunities for new businesses and investors looking to capitalize on the industry&#8217;s long-term potential.</p>
<p>Lower market prices have made it easier for entrepreneurs to enter the cannabis space, purchasing businesses or investing in startups at a fraction of the cost seen during the initial cannabis boom. As established players consolidate or exit, newcomers are stepping in with innovative approaches, such as niche products, craft cannabis, or tech-driven solutions, seeking to capture underserved segments of the market.</p>
<p>The market&#8217;s downward pressure on prices has also expanded access to consumers, leading to increased demand, especially among recreational users. Additionally, public support for cannabis remains strong, with growing recognition of its medicinal and therapeutic benefits, further driving consumption.</p>
<p>While California&#8217;s cannabis market is at a low, this period is fostering a reimagining of the industry. Savvy entrepreneurs and investors view this as a prime opportunity to enter or expand in the cannabis space, positioning themselves for future growth as the market stabilizes and regulations evolve.</p>
<p><strong>Examples of Cannabis Businesses In California On The Market Today:&nbsp;</strong></p>
<ul>
<li><a href="https://greenlifebusiness.com/property/fully-operational-cannabis-dispensary-retail-business-for-sale-through-receivership-call-for-offers-antioch-california-1462/">Lemonnade Dispensary For Sale Through Receivership CALL FOR OFFERS (Antioch, California) #1462</a></li>
<li><a href="https://greenlifebusiness.com/property/premier-cannabis-dispensary-retail-w-prime-location-for-sale-through-receivership-call-for-offers-due-by-july-30th-richmond-california-1448/">Call For Offers Premier Cannabis Dispensary Retail W/ Prime Location For Sale Through Receivership CALL FOR OFFERS Due By August 16th (Richmond, California) #1448</a></li>
<li><a href="https://greenlifebusiness.com/property/city-of-san-diego-cannabis-dispensary-license-for-sale-near-college-san-diego-california-1519/">City of San Diego Cannabis Dispensary License For Sale NEAR College (San Diego, California) #1519</a></li>
<li><a href="https://greenlifebusiness.com/property/prime-location-operational-dispensary-delivery-business-for-sale-west-hollywood-california-1505/">PRIME Location Operational Dispensary &amp; Delivery Business For Sale (West Hollywood, California) #1505</a></li>
</ul>
<ul>
<li><a href="https://greenlifebusiness.com/property/pre-ico-dispensary-license-relocatable-for-the-city-of-los-angeles-los-angeles-california-1522/">Pre ICO Dispensary License Relocatable for the City of Los Angeles (Los Angeles, California) #1522</a></li>
</ul>
<p>To View California or Nationwide Listings For Sale please Visit <a href="http://greenlifebusiness.com">greenlifebusiness.com</a>. To get further information on a business or get an evaluation for your business call Green Life Business Group at 619-653-0483 or email at <a href="mailto:sales@glbgroupinc.com">sales@glbgroupinc.com</a>.</p>


Cannabis

Increase in Demand For California Cannabis Assets Now That Market Is At All Time Low

<p><strong>Solid Power, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDP#NASDAQ">SLDP</a>) stock is trading higher on Friday after the company was selected by the U.S. Department of Energy Office of Manufacturing and Energy Supply Chains to start negotiations for up to $50 million in <a href="https://www.benzinga.com/news/24/09/40955243/solid-power-says-it-is-selected-by-u-s-department-of-energy-for-up-to-50m-award-negotiation-for-cont">federal funding</a>.</p>
<p><strong>The Details:</strong> Federal funding, via the Bipartisan Infrastructure Law, supports creating a continuous manufacturing process for sulfide-based solid electrolyte materials.</p>
<p>The sulfide-based solid electrolyte material plays an integral part in the expected performance advancements in energy density, safety, stability and cost of advanced all-solid-state batteries. Currently, Solid Power can produce up to 30 metric tons of electrolyte per year. Through this project, Solid Power expects to increase its production capability to 75 metric tons in 2026 and 140 metric tons in 2028.</p>
<p>&#8220;We view our selection for funding by the U.S. Department of Energy as validation of the promise sulfide-based all-solid-state batteries hold,&#8221; said<strong> John Van Scoter</strong>, President and CEO of Solid Power. </p>
<p>&#8220;By adopting a continuous manufacturing process for our electrolyte, we expect to be able to meet anticipated near-term demand and set Solid Power up to become the leading global producer of sulfide-based solid electrolyte.&#8221;</p>
<p><strong>How To Buy Solid Power Shares</strong></p>
<p>By now you're likely curious about how to participate in the market for Solid Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDP#NASDAQ">SLDP</a>) &#8211; be it to purchase shares, or even attempt to bet against the company.</p>
<p>Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. </p>
<p>In the the case of Solid Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDP#NASDAQ">SLDP</a>), which is trading at $1.49 as of publishing time, $100 would buy you 67.11 shares of stock.</p>
<p>If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/news/24/09/40939510/palantir-stock-hits-52-week-highs-thursday-whats-going-on">Palantir Stock Hits 52-Week Highs Thursday: What&#8217;s Going On?</a></strong></p>
<p><strong>SLDP Price Action:</strong> At the time of publication, Solid Power shares are moving 12.8% higher at $1.50, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><em>Image: 791333 from Pixabay.</em></p>


News

Movers

SLDP

What's Going On With Solid Power Shares Friday?

<p>B of A Securities  analyst Sara Senatore   maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Buy and raises the price target from $184 to $195.</p>


Price Target

Analyst Ratings

B of A Securities Maintains Buy on Darden Restaurants, Raises Price Target to $195

<p>Canaccord Genuity  analyst Richard Close   maintains Progyny (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>) with a Hold and lowers the price target from $24 to $18.</p>


PGNY

Canaccord Genuity Maintains Hold on Progyny, Lowers Price Target to $18

<p>B of A Securities  analyst Wamsi Mohan   maintains Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) with a Buy and raises the price target from $46 to $51.</p>


B of A Securities Maintains Buy on Corning, Raises Price Target to $51

WIIM

BNED

SNBR

Shares of retail companies are trading lower amid a possible selloff as the market pulls back from recent strength earlier this week.

US Secret Service Internal Investigation Reveals Communication Gaps And Lack Of Diligence Before July 13 Trump Shooting; Acting Director Calls For 'Paradigm Shift' And Acknowledges Failure To Provide Clear Guidance To Local Law Enforcement

Macro Notification

Econ #s

General

US Oil Rig Count Unchanged At 488, Down 19 YoY; NatGas Rigs Down 1 To 96; Gulf Of Mexico Rigs Down 1, Texas Up 2, Permian Up 1

<p>Deep-pocketed investors have adopted a bearish approach towards ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ARM usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 18 extraordinary options activities for ARM Holdings. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 22% leaning bullish and 77% bearish. Among these notable options, 7 are puts, totaling $290,559, and 11 are calls, amounting to $390,679.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $110.0 to $270.0 for ARM Holdings during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in ARM Holdings's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to ARM Holdings's substantial trades, within a strike price spectrum from $110.0 to $270.0 over the preceding 30 days.</p>
<h3>ARM Holdings Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726851814_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ARM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$16.05</td>
<td>$15.9</td>
<td>$16.05</td>
<td>$270.00</td>
<td>$80.2K</td>
<td>228</td>
<td style="text-align: right;">130</td>
</tr>
<tr>
<td>ARM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/01/24</td>
<td>$35.75</td>
<td>$33.25</td>
<td>$33.67</td>
<td>$170.00</td>
<td>$77.6K</td>
<td>0</td>
<td style="text-align: right;">23</td>
</tr>
<tr>
<td>ARM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$10.85</td>
<td>$10.7</td>
<td>$10.85</td>
<td>$125.00</td>
<td>$54.2K</td>
<td>1.3K</td>
<td style="text-align: right;">242</td>
</tr>
<tr>
<td>ARM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$22.95</td>
<td>$20.8</td>
<td>$22.0</td>
<td>$160.00</td>
<td>$50.6K</td>
<td>26</td>
<td style="text-align: right;">23</td>
</tr>
<tr>
<td>ARM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$16.6</td>
<td>$16.4</td>
<td>$16.4</td>
<td>$270.00</td>
<td>$39.3K</td>
<td>228</td>
<td style="text-align: right;">25</td>
</tr>
</tbody>
</table>
</p>
<h3>About ARM Holdings</h3>
<p>Arm Holdings is the IP owner and developer of the ARM architecture (ARM stands for Acorn RISC Machine), which is used in 99% of the world's smartphone CPU cores, and it also has high market share in other battery-powered devices like wearables, tablets, or sensors. Arm licenses its architecture for a fee, offering different types of licenses depending on the flexibility the customer needs. Customers like Apple or Qualcomm buy architectural licenses, which allows them to modify the architecture and add or delete instructions to tailor the chips to their specific needs. Other clients directly buy off-the-shelf designs from Arm. Off-the-shelf and architectural customers pay a royalty fee per chip shipped.</p>
<p>After a thorough review of the options trading surrounding ARM Holdings, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is ARM Holdings Standing Right Now?</h3>
<ul>
<li>With a volume of 2,690,796, the price of ARM is down -1.12% at $139.01. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 56 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest ARM Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

What the Options Market Tells Us About ARM Holdings

<p>Deep-pocketed investors have adopted a bullish approach towards Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SQ usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Block. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 62% leaning bullish and 37% bearish. Among these notable options, 3 are puts, totaling $200,280, and 5 are calls, amounting to $199,426.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $55.0 and $95.0 for Block, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Block's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Block's significant trades, within a strike price range of $55.0 to $95.0, over the past month.</p>
<h3>Block Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726851809_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SQ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.1</td>
<td>$6.0</td>
<td>$6.1</td>
<td>$67.50</td>
<td>$123.8K</td>
<td>1.2K</td>
<td style="text-align: right;">203</td>
</tr>
<tr>
<td>SQ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$4.85</td>
<td>$4.8</td>
<td>$4.8</td>
<td>$65.00</td>
<td>$48.4K</td>
<td>2.3K</td>
<td style="text-align: right;">104</td>
</tr>
<tr>
<td>SQ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.0</td>
<td>$7.85</td>
<td>$7.96</td>
<td>$65.00</td>
<td>$47.7K</td>
<td>7.0K</td>
<td style="text-align: right;">62</td>
</tr>
<tr>
<td>SQ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.75</td>
<td>$5.7</td>
<td>$5.75</td>
<td>$85.00</td>
<td>$40.2K</td>
<td>1.4K</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>SQ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$1.97</td>
<td>$1.94</td>
<td>$1.97</td>
<td>$70.00</td>
<td>$37.6K</td>
<td>3.7K</td>
<td style="text-align: right;">403</td>
</tr>
</tbody>
</table>
</p>
<h3>About Block</h3>
<p>Founded in 2009, Block provides payment services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. In 2023, Square's payment volume was a little over $200 million.</p>
<h3>Present Market Standing of Block</h3>
<ul>
<li>With a volume of 3,661,976, the price of SQ is down -1.49% at $67.62. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 41 days.</li>
</ul>
<h3>What The Experts Say On Block</h3>
<p>A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $81.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Buy rating on Block with a target price of $92.<br />
&#x2A; Reflecting concerns, an analyst from New Street Research lowers its rating to Neutral with a new price target of $70.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Block, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Block Unusual Options Activity

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Vertiv Hldgs</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VRT, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 13 options trades for <strong>Vertiv Hldgs</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 23% bullish and 38%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $57,810, and 12, calls, for a total amount of $1,243,555.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $75.0 to $130.0 for Vertiv Hldgs over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Vertiv Hldgs's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Vertiv Hldgs's whale trades within a strike price range from $75.0 to $130.0 in the last 30 days. </p>
<h3>Vertiv Hldgs Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726851803_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>VRT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$18.6</td>
<td>$18.4</td>
<td>$18.6</td>
<td>$82.50</td>
<td>$226.9K</td>
<td>437</td>
<td style="text-align: right;">123</td>
</tr>
<tr>
<td>VRT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$5.6</td>
<td>$5.4</td>
<td>$5.5</td>
<td>$115.00</td>
<td>$165.0K</td>
<td>1.6K</td>
<td style="text-align: right;">312</td>
</tr>
<tr>
<td>VRT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$8.2</td>
<td>$7.9</td>
<td>$7.9</td>
<td>$85.00</td>
<td>$158.0K</td>
<td>3.1K</td>
<td style="text-align: right;">225</td>
</tr>
<tr>
<td>VRT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$5.6</td>
<td>$5.4</td>
<td>$5.5</td>
<td>$130.00</td>
<td>$118.2K</td>
<td>570</td>
<td style="text-align: right;">216</td>
</tr>
<tr>
<td>VRT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$2.45</td>
<td>$2.35</td>
<td>$2.43</td>
<td>$94.00</td>
<td>$113.3K</td>
<td>209</td>
<td style="text-align: right;">512</td>
</tr>
</tbody>
</table>
</p>
<h3>About Vertiv Hldgs</h3>
<p>Vertiv Holdings Co brings together hardware, software, analytics and ongoing services to ensure its customers vital applications run continuously, perform optimally and grow with their business needs. The company solves the important challenges faced by data centers, communication networks and commercial and industrial facilities with a portfolio of power, cooling and IT infrastructure solutions and services that extends from the cloud to the edge of the network. Its services include critical power, thermal management, racks and enclosures, monitoring and management, and other services. Its three business segments include the Americas, Asia Pacific; and Europe, Middle East &amp; Africa.</p>
<p>Having examined the options trading patterns of Vertiv Hldgs, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Vertiv Hldgs's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 3,157,242, the VRT's price is up by 0.71%, now at $92.71. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 33 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Vertiv Hldgs options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Behind the Scenes of Vertiv Hldgs's Latest Options Trends

<p>BTIG  analyst Peter Saleh   maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Buy and raises the price target from $175 to $195.</p>


BTIG Maintains Buy on Darden Restaurants, Raises Price Target to $195

Federal Reserve

Fed's Bowman Says Such An Approach Would Avoid Unnecessarily Stoking Demand; Economy Remains Strong And Labor Market Remains Near Full Employment; My Reading Of Labor Market Data Has Become More Uncertain Because Of Measurement Challenges, Difficulty Assessing Immigration Impact; Respect And Appreciate That Colleagues Preferred To Go With A Larger Reduction, Remain Committed To Working With Them To Ensure Policy Is Appropriately Positioned To Achieve Dual Mandate Goals

Fed's Bowman On Dissent Says Agreed Was Appropriate At This Meeting To Recalibrate Fed Funds Rate Level But Preferred A Smaller First Move; Sees Risk That The Fomc's Larger Policy Action Could Be Interpreted As A Premature Declaration Of Victory On Inflation; We Have Not Yet Achieved Inflation Goal; Believe Moving At A Measured Pace Toward A More Neutral Policy Stance Will Ensure Further Progress Is Made In Returning Inflation To 2% Goal

<p>Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) has outperformed the market over the past 10 years by 6.87% on an annualized basis producing an average annual return of 18.08%. Currently, Apollo Global Management has a market capitalization of $70.17 billion. </p>
<p><strong>Buying $1000 In APO:</strong> If an investor had bought $1000 of APO stock 10 years ago, it would be worth <strong>$5,251.92</strong> today based on a price of $123.21 for APO at the time of writing.</p>
<h3>Apollo Global Management's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726851693_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

$1000 Invested In Apollo Global Management 10 Years Ago Would Be Worth This Much Today

<p>Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 7.39% on an annualized basis producing an average annual return of 18.6%. Currently, Insmed has a market capitalization of $12.71 billion. </p>
<p><strong>Buying $100 In INSM:</strong> If an investor had bought $100 of INSM stock 10 years ago, it would be worth <strong>$561.05</strong> today based on a price of $73.95 for INSM at the time of writing.</p>
<h3>Insmed's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726851688_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


INSM

Here's How Much You Would Have Made Owning Insmed Stock In The Last 10 Years

<p>In the latest quarter, 5 analysts provided ratings for Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $23.0, along with a high estimate of $40.00 and a low estimate of $8.00. Surpassing the previous average price target of $22.80, the current average has increased by 0.88%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726851677_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The perception of Capricor Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jason McCarthy</td>
<td>Maxim Group</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Capricor Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Capricor Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Capricor Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Capricor Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CAPR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Capricor Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Capricor Therapeutics</h2>
<p>Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.</p>
<h3>Breaking Down Capricor Therapeutics's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Capricor Therapeutics displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>1.38%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Capricor Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of <strong>-276.97%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-73.49%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Capricor Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-25.08%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Capricor Therapeutics's debt-to-equity ratio is below the industry average at <strong>0.16</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CAPR

Deep Dive Into Capricor Therapeutics Stock: Analyst Perspectives (5 Ratings)

<p>10 analysts have expressed a variety of opinions on Banc of California (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BANC#NYSE">BANC</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $14.8, a high estimate of $17.00, and a low estimate of $13.00. A 1.33% drop is evident in the current average compared to the previous average price target of $15.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726851663_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Banc of California is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Michael Rose</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$16.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Terrell</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Andrew Terrell</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Christopher Mcgratty</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Banc of California. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Banc of California compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Banc of California's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Banc of California's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BANC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Banc of California analyst ratings.</strong></a></p>
<h2>Delving into Banc of California's Background</h2>
<p>Banc of California Inc is a financial holding company. It offers banking and financial services. The company's services include banking services, lending services, and private banking services. Its deposit and banking product and service offerings include checking, savings, money market, certificates of deposit, and retirement accounts. Lending activities are focused on providing financing to California's diverse private businesses, entrepreneurs, and communities, and loans are often secured by California commercial and residential real estate. The company has one reportable segment named Commercial banking.</p>
<h3>Understanding the Numbers: Banc of California's Finances</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Banc of California's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>383.32%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Banc of California's net margin is impressive, surpassing industry averages. With a net margin of <strong>8.0%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Banc of California's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>0.7%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Banc of California's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.06%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.82</strong>, caution is advised due to increased financial risk.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BANC

A Glimpse Into The Expert Outlook On Banc of California Through 10 Analysts

<p>TD Cowen  analyst Brendan Smith   maintains Ginkgo Bioworks Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>) with a Buy and raises the price target from $3 to $10.</p>


TD Cowen Maintains Buy on Ginkgo Bioworks Holdings, Raises Price Target to $10

APTV

INDY

CNBC Final Trades: Samsara, Constellation Energy, Aptiv, iShares India 50 ETF

Fidelity Digital Health ETF declares quarterly distribution of $0.0110

FDHT

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Fidelity Digital Health ETF

Overview

Fidelity Digital Health ETF (BATS:FDHT), Quote.Headers.trade-ideas